Table 2 Therapeutic approaches and pharmacological therapies for VS.
From: Hearing loss and vestibular schwannoma: new insights into Schwann cells implication
Vestibular schwannoma | ||
|---|---|---|
Therapy | Target | Possible mechanism |
Watch and scan | Small tumors (<1 cm) | |
Surgery | Larger tumors with acoustic nerve compression | Tumor removal |
Radiation | Small lesions | Reduces tumor volume and preserve the nerve’s function |
Lapatinib | ErbB family protein inhibitors | Inhibits the tyrosine kinase activity associated with two oncogenes, EGFR and HER2/neu |
Ponatinib | PDGFR family proteins | Inhibition of cell proliferation, migration and invasion |
Bevacizumab | VEGFR | Inhibition of VEGF-R-mediated angiogenesis |
Crizotinib | HGFR | Inhibitor of receptor tyrosine kinases including ALK, HGFR and RON. |
OSU-03012/AR12 | PI3K/AKT pathway | Inhibitors of AKT signalling |
OSU-HDAC42/AR42 | ||
Erlotinib | EGFR-Ras-ERK | Inhibits tumor proliferation |
Rapamycin | mTORC1 | mTORC1 inhibitors |
Everolimus | ||
AZD2014 + Dasatinib | mTORC 1/2 | Inhibit cell growth and proliferation |
CXCR4 inhibitor | CXCR4 | CXCR4 inhibitor |
Mifepristone | NF-κB | Decreases cell metabolism and proliferation |
